{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:30:18Z","timestamp":1758403818265},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9,1]]},"DOI":"10.1093\/infdis\/jir385","type":"journal-article","created":{"date-parts":[[2011,8,15]],"date-time":"2011-08-15T18:39:10Z","timestamp":1313433550000},"page":"741-752","source":"Crossref","is-referenced-by-count":18,"title":["A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy"],"prefix":"10.1093","volume":"204","author":[{"given":"Roger","family":"Paredes","sequence":"first","affiliation":[{"name":"Institut de Recerca de la SIDA\u2013IrsiCaixa"},{"name":"Lluita Contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"}]},{"given":"Maria Carmen","family":"Puertas","sequence":"additional","affiliation":[{"name":"Institut de Recerca de la SIDA\u2013IrsiCaixa"}]},{"given":"Wendy","family":"Bannister","sequence":"additional","affiliation":[{"name":"Research Department of Infection & Population Health, University College London, United Kingdom"}]},{"given":"M\u00f3nica","family":"Kisic","sequence":"additional","affiliation":[{"name":"Centro de Biolog\u00eda Molecular \u201cSevero Ochoa\u201d (CSIC-UAM), Madrid, Spain"}]},{"given":"Alessandro","family":"Cozzi-Lepri","sequence":"additional","affiliation":[{"name":"Research Department of Infection & Population Health, University College London, United Kingdom"}]},{"given":"Christian","family":"Pou","sequence":"additional","affiliation":[{"name":"Institut de Recerca de la SIDA\u2013IrsiCaixa"}]},{"given":"Roc\u00edo","family":"Bellido","sequence":"additional","affiliation":[{"name":"Institut de Recerca de la SIDA\u2013IrsiCaixa"}]},{"given":"Gilberto","family":"Betancor","sequence":"additional","affiliation":[{"name":"Centro de Biolog\u00eda Molecular \u201cSevero Ochoa\u201d (CSIC-UAM), Madrid, Spain"}]},{"given":"Johannes","family":"Bogner","sequence":"additional","affiliation":[{"name":"Medizinische Poliklinik, Munich, Germany"}]},{"given":"Panagiotis","family":"Gargalianos","sequence":"additional","affiliation":[{"name":"Special Infectious Unit\/First Department of Medicine, Athens General Hospital, Greece"}]},{"given":"D\u00e9nes","family":"B\u00e1nhegyi","sequence":"additional","affiliation":[{"name":"Immunology Department, Szent Lszl Hospital, Budapest, Hungary"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[{"name":"Institut de Recerca de la SIDA\u2013IrsiCaixa"},{"name":"Lluita Contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"}]},{"given":"Jens","family":"Lundgren","sequence":"additional","affiliation":[{"name":"Copenhagen HIV Programme, University of Copenhagen"},{"name":"Department of Infectious Diseases, Centre for Viral Disease KMA, Rigshospitalet, Copenhagen, Denmark"}]},{"given":"Luis","family":"Men\u00e9ndez-Arias","sequence":"additional","affiliation":[{"name":"Centro de Biolog\u00eda Molecular \u201cSevero Ochoa\u201d (CSIC-UAM), Madrid, Spain"}]},{"given":"Javier","family":"Martinez-Picado","sequence":"additional","affiliation":[{"name":"Institut de Recerca de la SIDA\u2013IrsiCaixa"},{"name":"Instituci\u00f3 Catalana de Recerca Avan\u00e7ada (ICREA), Barcelona, Spain"}]},{"name":"The EuroSIDA Study Group","sequence":"additional","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2011,9,1]]},"reference":[{"key":"key\n\t\t\t\t20180328173623_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.antiviral.2009.02.189","article-title":"Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naive patients","volume":"82","author":"Hachiya","year":"2009","journal-title":"Antiviral Res"},{"key":"key\n\t\t\t\t20180328173623_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1128\/AAC.00904-07","article-title":"Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 reverse transcriptase facilitates dual resistance to zidovudine and lamivudine","volume":"52","author":"Zelina","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328173623_bib3","doi-asserted-by":"crossref","first-page":"22222","DOI":"10.1074\/jbc.M803521200","article-title":"Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3\u2032-azido-3\u2032-deoxythymidine through both RNase H-dependent and -independent mechanisms","volume":"283","author":"Ehteshami","year":"2008","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20180328173623_bib4","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1371\/journal.pmed.0040335","article-title":"N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance","volume":"4","author":"Yap","year":"2007","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20180328173623_bib5","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1128\/AAC.00646-07","article-title":"Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine","volume":"51","author":"Ntemgwa","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328173623_bib6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1073\/pnas.0609642104","article-title":"Mutations in the connection domain of HIV-1 reverse transcriptase increase 3\u2032-azido-3\u2032-deoxythymidine resistance","volume":"104","author":"Nikolenko","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20180328173623_bib7","doi-asserted-by":"crossref","first-page":"6837","DOI":"10.1128\/JVI.02820-06","article-title":"Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3\u2032-azido-3\u2032-deoxythymidine resistance","volume":"81","author":"Delviks-Frankenberry","year":"2007","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180328173623_bib8","doi-asserted-by":"crossref","first-page":"7852","DOI":"10.1128\/JVI.02203-06","article-title":"Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3\u2032-azido-3\u2032-dideoxythymidine","volume":"81","author":"Brehm","year":"2007","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180328173623_bib9","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1128\/AAC.00870-09","article-title":"Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance","volume":"54","author":"Gupta","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328173623_bib10","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1086\/651168","article-title":"Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase","volume":"201","author":"von Wyl","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328173623_bib11","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/QAD.0b013e328336781d","article-title":"N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations","volume":"24","author":"Radzio","year":"2010","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328173623_bib12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/QAI.0b013e3181cbd235","article-title":"Connection domain mutations in treatment-experienced patients in the OPTIMA trial","volume":"54","author":"Dau","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328173623_bib13","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1371\/journal.pmed.0040346","article-title":"Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing","volume":"4","author":"Gotte","year":"2007","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20180328173623_bib14","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study","volume":"363","author":"van Leth","year":"2004","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328173623_bib15","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(06)69861-9","article-title":"A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial","volume":"368","author":"MacArthur","year":"2006","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328173623_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00002030-200201040-00008","article-title":"Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study","volume":"16","author":"Matthews","year":"2002","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328173623_bib17","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1086\/339821","article-title":"Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study","volume":"185","author":"Cozzi-Lepri","year":"2002","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328173623_bib18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1310\/M47B-R51C-X0MC-K3GW","article-title":"Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study","volume":"3","author":"Keiser","year":"2002","journal-title":"HIV Clin Trials"},{"key":"key\n\t\t\t\t20180328173623_bib19","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1097\/00002030-200112070-00006","article-title":"Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients","volume":"15","author":"Phillips","year":"2001","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328173623_bib20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/QAD.0b013e3282f3cc35","article-title":"Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA","volume":"22","author":"Bannister","year":"2008","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328173623_bib21","first-page":"156","article-title":"Update of the drug resistance mutations in HIV-1: December 2010","volume":"18","author":"Johnson","year":"2010","journal-title":"Top HIV Med"},{"key":"key\n\t\t\t\t20180328173623_bib22","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328173623_bib23","doi-asserted-by":"crossref","first-page":"7186","DOI":"10.1128\/JVI.02084-05","article-title":"Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors","volume":"80","author":"Svicher","year":"2006","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180328173623_bib24","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1128\/JCM.37.9.2943-2951.1999","article-title":"Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing","volume":"37","author":"Martinez-Picado","year":"1999","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180328173623_bib25","doi-asserted-by":"crossref","first-page":"7434","DOI":"10.1128\/JVI.00487-09","article-title":"Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility","volume":"83","author":"Puertas","year":"2009","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180328173623_bib26","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1177\/135965350801300710","article-title":"Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy","volume":"13","author":"Buzon","year":"2008","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180328173623_bib27","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jmb.2008.07.030","article-title":"Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region","volume":"382","author":"Kisic","year":"2008","journal-title":"J Mol Biol"},{"key":"key\n\t\t\t\t20180328173623_bib28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jmb.2005.04.004","article-title":"Suppression of multidrug-resistant HIV-1 reverse transcriptase primer unblocking activity by alpha-phosphate-modified thymidine analogues","volume":"349","author":"Matamoros","year":"2005","journal-title":"J Mol Biol"},{"key":"key\n\t\t\t\t20180328173623_bib29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1006\/abio.2001.5045","article-title":"An integrated system to study multiply substituted human immunodeficiency virus type 1 reverse transcriptase","volume":"292","author":"Boretto","year":"2001","journal-title":"Anal Biochem"},{"key":"key\n\t\t\t\t20180328173623_bib30","doi-asserted-by":"crossref","first-page":"25988","DOI":"10.1016\/S0021-9258(18)35706-5","article-title":"Mechanism and fidelity of HIV reverse transcriptase","volume":"267","author":"Kati","year":"1992","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20180328173623_bib31","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/nar\/25.7.1383","article-title":"Mispair extension fidelity of human immunodeficiency virus type 1 reverse transcriptases with amino acid substitutions affecting Tyr115","volume":"25","author":"Mart\u00edn-Hern\u00e1ndez","year":"1997","journal-title":"Nucleic Acids Res"},{"key":"key\n\t\t\t\t20180328173623_bib32","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1021\/bi952058+","article-title":"HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors","volume":"35","author":"Spence","year":"1996","journal-title":"Biochemistry"},{"key":"key\n\t\t\t\t20180328173623_bib33","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1110\/ps.072829007","article-title":"Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses","volume":"16","author":"Xia","year":"2007","journal-title":"Protein Sci"},{"key":"key\n\t\t\t\t20180328173623_bib34","doi-asserted-by":"crossref","first-page":"16636","DOI":"10.1021\/bi981830g","article-title":"Studies on the effects of truncating alpha-helix E' of p66 human immunodeficiency virus type 1 reverse transcriptase on template-primer binding and fidelity of DNA synthesis","volume":"37","author":"Men\u00e9ndez-Arias","year":"1998","journal-title":"Biochemistry"},{"key":"key\n\t\t\t\t20180328173623_bib35","volume-title":"Guide to management of HIV drug resistance, antiretrovirals pharmacokinetics and viral hepatitis in HIV infected subjects","author":"Clotet","year":"2010","edition":"10th ed"},{"key":"key\n\t\t\t\t20180328173623_bib36","doi-asserted-by":"crossref","first-page":"27470","DOI":"10.1074\/jbc.M104342200","article-title":"Functional characterization of chimeric reverse transcriptases with polypeptide subunits of highly divergent HIV-1 group M and O strains","volume":"276","author":"Men\u00e9ndez-Arias","year":"2001","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20180328173623_bib37","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1073\/pnas.121055998","article-title":"Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase","volume":"98","author":"Tachedjian","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20180328173623_bib38","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1021\/bi051915z","article-title":"Effects of efavirenz binding on the subunit equilibria of HIV-1 reverse transcriptase","volume":"45","author":"Venezia","year":"2006","journal-title":"Biochemistry"},{"key":"key\n\t\t\t\t20180328173623_bib39","doi-asserted-by":"crossref","first-page":"26966","DOI":"10.1074\/jbc.M110.105775","article-title":"N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation","volume":"285","author":"Biondi","year":"2010","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20180328173623_bib40","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"31","author":"Rhee","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"key\n\t\t\t\t20180328173623_bib41","article-title":"Prospective comparison of nevirapine and atazanavir\/ritonavir both combined with tenofovir DF\/emtricitabine in treatment-naive HIV-1 infected patients: ARTEN study week 48 results [Poster LBPEB07]","volume-title":"5th IAS Conference on HIV Pathogenesis, Treatment and Prevention","author":"Soriano","year":"2009"},{"key":"key\n\t\t\t\t20180328173623_bib42","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1086\/324629","article-title":"Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression","volume":"34","author":"Negredo","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328173623_bib43","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/00002030-200207050-00010","article-title":"Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine","volume":"16","author":"Negredo","year":"2002","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328173623_bib44","first-page":"A35","article-title":"Effect of mutations in the RT connection domain on phenotypic susceptibility and virologic response to etravirine","volume":"14","author":"Vingerhoets","year":"2009","journal-title":"Antivir Ther"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/204\/5\/741\/16865372\/jir385.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T23:24:26Z","timestamp":1712705066000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/204\/5\/741\/796618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,1]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2011,9,1]]},"published-print":{"date-parts":[[2011,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jir385","relation":{},"ISSN":["1537-6613","0022-1899"],"issn-type":[{"type":"electronic","value":"1537-6613"},{"type":"print","value":"0022-1899"}],"subject":[],"published-other":{"date-parts":[[2011,9,1]]},"published":{"date-parts":[[2011,9,1]]}}}